摘要
INTRODUCTION Acute kidney injury (AKI) is a clinical syndrome characterized by a rapid decline in renal function over a short period. AKI is a major global public health challenge due to its high incidence and associated mortality.[1] Its etiological factors include nephrotoxic drugs, sepsis, ischemia-reperfusion (I/R) injury, major surgical procedures, and rhabdomyolysis, all of which can cause acute damage to the renal parenchyma. The pathogenesis of AKI is complex and multifactorial. Currently, the clinical management of AKI primarily involves addressing the underlying causes, providing supportive care, and employing interventions such as blood purification and renal replacement therapy. The current lack of specific pharmacological treatments for AKI underscores the urgent need to identify novel therapeutic agents and molecular targets. For centuries, traditional Chinese medicine (TCM) has been widely used to prevent and treat renal diseases. More recently, phytochemicals derived from TCM herbs have shown promise in various AKI models. TCM involves a multi-faceted approach that includes the utilization of multiple active components, targets, and pathways; as such, it provides benefits in the clinical management of AKI.[2] However, the complexity of many TCM products has led to a poor understanding of their molecular mechanisms and a lack of worldwide acceptance. In this article, we summarize recent evidence of the clinical effectiveness and underlying mechanisms of TCM-based interventions in AKI, providing insights into their potential role in clinical prevention and therapeutic strategies. NOVEL MOLECULAR MECHANISMS UNDERLYING THE DEVELOPMENT OF AKI The onset of AKI is significantly influenced by inflammatory mediators, particularly those produced by damaged renal tissue or activated immune cells. Interleukins (ILs), which are key elements of the cytokine network, play diverse roles in AKI development, including in inflammation, tissue repair, and injury to distant organs. In addition, ILs mitigate AKI by promoting interactions among renal resident cells, immune cells, and fibroblasts.[3] Macrophages contribute to renal inflammation and repair by changing their phenotype and function. They demonstrate a gradual shift to an anti-inflammatory phenotype due to the tissue microenvironment regulating the suppression of glycolysis-related genes and the promotion of oxidative phosphorylation, which is crucial for tissue repair and remodeling.[4] In AKI, renal epithelial cell loss is not always evident; however, cell death often occurs in severe cases. Apoptosis and regulated necrosis are the standard types of regulatory cell death observed in AKI. Apoptosis, a process that does not provoke an immune reaction, may cause the death of renal tubular cells during their development and regeneration. Whereas regulated necrosis, in which the integrity of the plasma membrane is compromised, results in the death of renal cells after AKI. Evidence strongly suggests that forms of regulated necrosis, including ferroptosis, necroptosis, and pyroptosis, are central to the pathophysiology of acute tubular necrosis, glomerular loss, and renal fibrosis.[5] There is also increasing evidence that the gut microbiota influences AKI development, underscoring its significant link to renal physiology and pathophysiology.[6] For example, quantitative disturbances in the intestinal flora have been observed in AKI patients, and orally administering Lactobacillus casei CERELA 431 has been shown to reduce inflammatory factor production in mice with sepsis-induced AKI. Furthermore, bacteria from the Enterobacteriaceae family, including Escherichia coli and Klebsiella oxytoca, have been found to produce D-alanine in the intestines, and oral administration of D-alanine improves kidney damage in mice with I/R-induced AKI (I/R-AKI). In summary, clinical and experimental findings demonstrate that the gut microbiota and its metabolites influence the progression and outcome of AKI [Figure 1]. Figure 1.: Novel molecular mechanisms of acute kidney injury. IL-6, interleukin 6; IL-17, interleukin 17; TNF-α, tumor necrosis factor α; ROS, reactive oxygen species. NATURAL COMPOUNDS FOUND TO BE EFFECTIVE ANTI-AKI AGENTS Pharmacological research has demonstrated that Ligusticum chuanxiong exhibits analgesic effects, promotes the proliferation of vascular endothelial cells, and provides protection against I/R-AKI. It also confers anti-inflammatory and protective benefits for both the cardiovascular and cerebrovascular systems. Tetramethylpyrazine (TMP), the primary alkaloid found in Ligusticum chuanxiong, exerts significant pharmacological effects on the vascular endothelium and circulatory system. It has also been shown to effectively prevent and treat arsenic-induced AKI (A-AKI) by reducing oxidative stress, suppressing inflammation, inhibiting apoptosis in renal tubular epithelial cells, and modulating autophagy. Recent findings suggest that TMP may alleviate A-AKI by resolving the autophagic flux blockade via a Yes1 associated transcriptional regulator (YAP1)-nuclear factor erythroid 2-related factor 2 (Nrf2)-p62-dependent pathway.[7] Isorhamnetin, a naturally occurring flavonol, also exhibits potent anti-inflammatory and antioxidant activities. Wang et al.[8] investigated its therapeutic potential in cisplatin-induced AKI (Cis-AKI) and found that it significantly attenuated apoptosis and inflammatory responses. In addition, a transcriptomic analysis of renal tissues indicated that isorhamnetin may exert renoprotective effects in Cis-AKI by enhancing fatty acid oxidation mediated by peroxisome proliferator activated receptor γ coactivator-1α (PGC-1α).[8] Treatment with isorhamnetin led to marked upregulation of PGC-1α and its downstream targets, perixisome proliferator-activated receptor α (PPARα) and carnitine palmitoyltransferase 1A (CPT1A), and improved lipid clearance and adenosine triphosphate (ATP) production.[8] These results highlight the therapeutic potential of isorhamnetin in mitigating Cis-AKI through PGC-1α-dependent regulation of mitochondrial energy metabolism. Zhang et al.[9] investigated the key redox mechanisms involved in Cis-AKI and developed a tailored photoacoustic imaging probe, AB-DiOH, capable of reversibly responding to hypochlorite (ClO−) and glutathione (GSH). Using this probe, they demonstrated that astragalin could inhibit excessive production of endogenous ClO−, indicating its potential as a therapeutic agent for AKI. The use of AB-DiOH in screening revealed that astragalin may modulate oxidative stress and influence regulated cell death pathways (e.g., ferroptosis and cuproptosis), with elevated GSH levels serving as a key indicator. To investigate the underlying mechanisms, the regulatory proteins associated with these pathways were examined. They found that in ferroptosis, the lipid peroxidation of polyunsaturated fatty acids on the cell membrane is catalyzed and that human glutathione peroxidase 4 (GPX4) plays a critical role in detoxifying lipid peroxides and protecting against oxidative damage. In cuproptosis, regulatory proteins, such as ferredoxin 1 (FDX1), the copper importer recombinant human high affinity copper uptake protein 1 (SLC31A1), and the copper exporter ATP7B, are involved in maintaining copper homeostasis. Astragalin administration resulted in reduced expression of FDX1 and SLC31A1, and a marked increase in ATP7B expression. These findings suggest that the therapeutic effects of astragalin are mediated by its capacity to inhibit oxidative stress, ferroptosis, and cuproptosis. Quercetin, the principal active compound in Abelmoschus manihot, has shown efficacy in treating coronavirus disease 2019 (COVID-19) and in preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) N protein-induced AKI in diabetic mice. Recent studies have revealed that the SARS-CoV-2 N protein directly binds to Smad3, activating the Smad3-cyclin-dependent kinase inhibitor 1A (p21) pathway and inducing AKI via G1 cell cycle arrest.[10] Therefore, targeting Smad3 may be a viable strategy for managing COVID-19-associated AKI (C-AKI). Quercetin appears to inhibit the interaction between the SARS-CoV-2 N protein and Smad3, thereby blocking Smad3 signaling and preventing Smad3-mediated cell death through the p16-dependent G1 arrest pathway.[10] In diabetic mice, particularly those that are older and have existing diabetic kidney disease, the SARS-CoV-2 N protein acts as a pathogenic factor, inducing severe AKI via the Smad3-dependent G1 cell cycle arrest pathway. In such mice, quercetin has been found to prevent C-AKI by inhibiting the SARS-CoV-2 N-Smad3-mediated apoptotic signaling pathway. Quercetin has also been identified as a potential anti-SARS-CoV-2 agent. Leonurine hydrochloride (LH), the primary active alkaloid in Leonurus japonicus, has recently been shown to modulate several pathological processes, including oxidative stress, inflammation, fibrosis, apoptosis, and metabolic dysregulation. A recent study investigated the role LH plays in the regulation of ferroptosis in Cis-AKI.[11] Given that the Nrf2 signaling pathway is a key regulator of oxidative stress and lipid peroxidation and is known to exert protective effects in Cis-AKI, it was expected and observed that knocking out Nrf2 exacerbated ferroptosis. This was mediated by increased expression of ferroptosis-related proteins and iron accumulation in vivo, which led to greater kidney injury. The results of in vitro experiments demonstrated that LH activated Nrf2 and reduced iron accumulation, lipid peroxidation, and ferroptosis. However, these protective effects were abolished in Nrf2-silenced cells. LH significantly improved renal function and reduced kidney injury biomarkers in Cis-AKI models. Importantly, LH activated the Nrf2 antioxidant pathway and attenuated both morphological and biochemical markers of ferroptosis in Cis-AKI. These findings suggest that Nrf2 activation confers renal protection, partly by suppressing lipid peroxide-driven ferroptosis, and highlight the therapeutic potential of LH in the treatment of Cis-AKI. CONCLUSION AND PERSPECTIVE AKI has diverse etiological factors, each with distinct pathogenic mechanisms. Early detection and intervention remain the cornerstones of the effective management of AKI, and the importance of early recovery in patients with AKI is well recognized. There are currently no specific pharmacological therapies for AKI, further clinical studies are required to validate potential treatments, and research on the use of TCM-based interventions for the prevention and treatment of AKI remains limited. Nonetheless, emerging evidence indicates that phytochemicals found in TCM products exert beneficial effects through multi-target and multi-pathway mechanisms and thus may offer unique advantages, such as reduced adverse effects and improved survival outcomes. As new research technologies and methodologies are developed and applied, we deepen our understanding of the mechanisms used by these phytochemicals and the pathological mechanisms of AKI. In turn, this will enable the long-term evaluation of their therapeutic efficacy and reinforce the role that TCM compounds play in the prevention and management of AKI.